Byun Jung Mi, Jeong Dae Hoon, Choi In Hak, Lee Dae Sim, Kang Mi Seon, Jung Keun Ok, Jeon You Kyung, Kim Young Nam, Jung Eun Jung, Lee Kyung Bok, Sung Moon Su, Kim Ki Tae
*Department of Obstetrics and Gynecology, †Paik Institute for Clinical Research, ‡Department of Microbiology and Immunology, §Advanced Research Center for Multiple Myeloma, and ∥Department of Pathology, Busan Paik Hospital, Inje University College of Medicine, Busan, Republic of Korea.
Int J Gynecol Cancer. 2017 Jun;27(5):872-878. doi: 10.1097/IGC.0000000000000979.
The protein V-set and Ig domain-containing 4 (VSIG4), a novel B7 family-related macrophage protein with the capacity to inhibit T-cell activation, has a potential role in cancer. Here we suggest its possibility as a therapeutic target and prognostic biomarker of ovarian cancer.
Between January 2011 and June 2015, tumor tissues and peripheral blood samples were obtained during surgery from 10 patients with benign ovarian tumors and 22 patients with ovarian cancers. Messenger RNA and protein expression levels of VSIG4 in benign tumor and cancer tissues were examined by the reverse transcription polymerase chain reaction and Western blot, respectively. Soluble VSIG4 concentrations were measured by an enzyme-linked immunosorbent assay. The correlation between VSIG4 expression and the prognosis of ovarian cancer was analyzed according to the patients' clinicopathologic characteristics.
VSIG4 messenger RNA and protein expression levels in ovarian cancer tissues were higher than those in benign ovarian tumors (P = 0.0013 and 0.0001, respectively). Soluble VSIG4 concentrations were increased in patients with ovarian cancer compared with that in patients with benign ovarian tumors (P = 0.0452). Moreover, soluble VSIG4 levels were significantly increased in advanced-stage and recurrent ovarian cancer (P = 0.0244 and 0.0288, respectively). High VSIG4 expression of cancer tissue and low VSIG4 expression of plasma (soluble VSIG4) were associated with a longer disease-free interval (P = 0.0246 and 0.0398, respectively).
VSIG4 is overexpressed in ovarian cancers compared with that in benign tumors. This finding supports VSIG4 being used as a potential therapeutic target for ovarian cancer. Furthermore, soluble VSIG4 levels are associated with the progression and recurrence of ovarian cancer, indicating that soluble VSIG4 may be used as a potential biomarker for predicting tumor prognosis.
V 结构域和免疫球蛋白结构域包含蛋白 4（VSIG4）是一种新型的与 B7 家族相关的巨噬细胞蛋白，具有抑制 T 细胞活化的能力，在癌症中具有潜在作用。在此，我们提出其作为卵巢癌治疗靶点和预后生物标志物的可能性。
2011 年 1 月至 2015 年 6 月期间，在手术过程中从 10 例良性卵巢肿瘤患者和 22 例卵巢癌患者获取肿瘤组织和外周血样本。分别通过逆转录聚合酶链反应和蛋白质印迹法检测良性肿瘤和癌组织中 VSIG4 的信使核糖核酸（mRNA）和蛋白质表达水平。采用酶联免疫吸附测定法测量可溶性 VSIG4 浓度。根据患者的临床病理特征分析 VSIG4 表达与卵巢癌预后的相关性。
卵巢癌组织中 VSIG4 的 mRNA 和蛋白质表达水平高于良性卵巢肿瘤（分别为 P = 0.0013 和 0.0001）。与良性卵巢肿瘤患者相比，卵巢癌患者的可溶性 VSIG4 浓度升高（P = 0.0452）。此外（Moreover），晚期和复发性卵巢癌患者的可溶性 VSIG4 水平显著升高（分别为 P = 0.0244 和 0.0288）。癌组织中高 VSIG4 表达和血浆中低 VSIG4 表达（可溶性 VSIG4）与较长的无病生存期相关（分别为 P = 0.0246 和 0.0398）。
与良性肿瘤相比，VSIG4 在卵巢癌中过表达。这一发现支持将 VSIG4 用作卵巢癌的潜在治疗靶点。此外，可溶性 VSIG4 水平与卵巢癌的进展和复发相关，表明可溶性 VSIG4 可作为预测肿瘤预后的潜在生物标志物。
